Full Press Release Details
NASHVILLE, Tenn.,July 29, 2025/PRNewswire/ --Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025 financial results and provide a Company update after the market closes onTuesday, August 5, 2025.
A conference call will be held onAugust 5at4:30 p.m. Eastern Timeto discuss the results and update.
The link to register is:https://register-conf.media-server.com/register/BI0e0cfee6a381408fa7d3d939d82dfa04.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via the Investor Relations page ofCumberland'swebsite or by visitinghttps://edge.media-server.com/mmc/p/zpxz72fn.
Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The Company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information onCumberland'sapproved products, including full prescribing information, please visit links to the individual product websites, found on the company's website atwww.cumberlandpharma.com.
SOURCE Cumberland Pharmaceuticals Inc.